

International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Precision Oncology Beyond Genomics: The Integration of Multi-Omics and Artificial Intelligence

Dr. Bhavna Rao¹, Dr. Anil Thomas², Mrs. Komal Shah³, Dr. Dinesh Kulkarni⁴, Mr. Rakesh Verma⁵

¹Professor Department of Drug Regulatory Sciences, Western Biomedical University, Nagpur, India bhavna.rao74@gmail.com

²Associate Professor Department of Pharmaceutics, Western Biomedical University, Nagpur, India anilthomas1990@gmail.com

³Assistant Professor Department of Pharmaceutical Analysis, Western Biomedical University, Nagpur, India komal.shah16@gmail.com

⁴Professor Department of Pharmacology, Western Biomedical University, Nagpur, India dineshk67@gmail.com

⁵Associate Professor Department of Pharmacognosy, Western Biomedical University, Nagpur, India rakeshverma58@gmail.com

ABSTRACT

Precision oncology has traditionally focused on genomic profiling to guide personalized cancer diagnosis and therapy. Although genomic medicine has significantly improved the identification of actionable mutations and targeted treatment strategies, genomic information alone cannot fully explain the remarkable biological complexity and clinical heterogeneity of cancer. Tumor behavior is influenced by multiple interconnected molecular layers, including epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics, and immunomics, which collectively regulate disease initiation, progression, therapeutic response, and resistance. The emergence of multi-omics technologies, combined with advances in artificial intelligence (AI), has enabled comprehensive characterization of cancer biology through integration of heterogeneous molecular and clinical datasets. Machine learning, deep learning, graph neural networks, transformer architectures, multimodal learning, and foundation models are increasingly capable of analyzing high-dimensional omics data alongside radiological imaging, digital pathology, electronic health records, and laboratory biomarkers. These computational approaches support improved cancer diagnosis, prognostic prediction, biomarker discovery, therapeutic selection, immunotherapy response prediction, drug discovery, and precision clinical decision-making. Despite remarkable progress, challenges remain regarding data harmonization, interoperability, computational complexity, explainability, ethical governance, regulatory validation, and equitable clinical implementation. This review provides a comprehensive overview of multi-omics integration and artificial intelligence in precision oncology, highlighting current applications, technological innovations, and future directions toward truly individualized cancer care.[1]

Keywords: Precision oncology, Multi-omics, Artificial intelligence, Genomics, Transcriptomics, Proteomics, Metabolomics, Machine learning, Precision medicine, Systems biology.

Article Info

Received: 05 December 2025, received in revised form: 15 December 2025, accepted: 20 December 2025, available online: 30 December 2025; Volume: 1; Issue: 5; Pages: 01-07.

Citation: Rao B., 2025. Precision Oncology Beyond Genomics: The Integration of Multi-Omics and Artificial Intelligence. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)* 1(2): 01-07.

DOI:

Introduction

Cancer is an extraordinarily complex disease driven by dynamic interactions among genetic mutations, epigenetic modifications, transcriptional regulation, protein expression, metabolic alterations, immune responses, and the tumor microenvironment. While advances in genomic sequencing have transformed precision oncology by identifying clinically actionable mutations and enabling targeted therapies, genomic information alone often fails to capture the complete biological diversity underlying cancer progression and therapeutic response.[2]

Patients harboring identical genomic mutations frequently exhibit markedly different clinical outcomes because tumor behavior is also influenced by gene expression patterns, post-translational protein modifications, metabolic pathways, immune-cell interactions, microbiome composition, and environmental factors. Consequently, modern precision oncology increasingly recognizes that comprehensive understanding of cancer requires integration of multiple biological layers rather than reliance on genomics alone.[3]

Recent advances in high-throughput omics technologies have enabled simultaneous measurement of genomic, epigenomic, transcriptomic, proteomic, metabolomic, lipidomic, and microbiomic information at unprecedented scale. These datasets provide complementary perspectives on tumor biology but generate enormous computational complexity that exceeds traditional analytical approaches.[4]

Artificial intelligence has emerged as the enabling technology capable of integrating these heterogeneous datasets into unified computational frameworks that support diagnosis, prognostic prediction, biomarker discovery, treatment selection, and individualized cancer management. The convergence of multi-omics and AI is therefore redefining the future of precision oncology by moving beyond single-dimensional molecular analysis toward comprehensive systems-level understanding of cancer biology.[5]

2. Evolution of Precision Oncology

The earliest era of precision oncology primarily relied on histopathological classification and anatomical staging to guide treatment decisions. Although these approaches remain fundamental to cancer diagnosis, they often failed to account for the molecular diversity observed among tumors with similar histological characteristics.[6]

The introduction of next-generation sequencing marked a transformative milestone by enabling comprehensive genomic profiling of individual tumors. Identification of driver mutations in genes such as EGFR, KRAS, BRAF, ALK, and HER2 facilitated the development of targeted therapies that significantly improved outcomes for selected patient populations.[7]

Despite these successes, clinicians soon recognized that genomic alterations alone were insufficient to explain therapeutic response, disease progression, or acquired drug resistance. Consequently, research shifted toward integrating additional molecular layers, including transcriptomics, epigenomics, proteomics, metabolomics, and immunomics, to obtain a more complete understanding of cancer biology.

Simultaneously, advances in artificial intelligence enabled computational analysis of these increasingly complex datasets. Machine learning and deep learning algorithms now integrate multi-omics information with radiology, pathology, and clinical records to generate individualized predictions that support precision medicine.[8]

Today, precision oncology is evolving into a systems biology discipline in which multiple molecular networks are analyzed collectively rather than independently, enabling more accurate characterization of tumor behavior and personalized therapeutic strategies.[9]

3. The Multi-Omics Landscape in Oncology

Multi-omics refers to the comprehensive integration of multiple biological data layers describing different aspects of cellular function. Each omics discipline contributes unique information regarding tumor development, progression, therapeutic response, and resistance mechanisms.[10]

Genomics identifies inherited and somatic DNA mutations responsible for oncogenesis, whereas epigenomics examines DNA methylation, histone modifications, and chromatin organization that regulate gene activity without altering nucleotide sequences. Transcriptomics evaluates messenger RNA expression patterns that reflect dynamic gene regulation, while proteomics investigates protein abundance, structure, and post-translational modifications responsible for cellular function.

Metabolomics characterizes small-molecule metabolites that represent downstream products of cellular metabolism and provide direct insight into biochemical activity. Lipidomics examines lipid metabolism and membrane biology, whereas microbiomics explores interactions between host microbial communities and cancer progression. Immunomics further evaluates immune-cell composition, cytokine signaling, and adaptive immune responses that influence therapeutic effectiveness.

Together, these complementary molecular layers provide a comprehensive systems-level representation of tumor biology that substantially exceeds the information available through genomic analysis alone.[11]

4. Artificial Intelligence for Multi-Omics Integration

The enormous complexity of multi-omics datasets presents substantial computational challenges due to their high dimensionality, heterogeneous data structures, and intricate biological interactions. Artificial intelligence has become indispensable for integrating these diverse molecular datasets into clinically meaningful predictive models.[12]

Machine learning algorithms identify complex nonlinear relationships among genomic, transcriptomic, proteomic, metabolomic, and clinical variables that would be difficult to recognize using conventional statistical techniques. Deep learning architectures automatically learn hierarchical representations from high-dimensional molecular data, eliminating the need for manual feature engineering while improving predictive performance.

Graph neural networks model biological interaction networks involving genes, proteins, signaling pathways, and metabolic processes, enabling AI to capture systems-level biological relationships. Transformer architectures and multimodal learning frameworks further integrate molecular information with radiological imaging, digital pathology, laboratory biomarkers, and electronic health records into unified patient representations.

These computational advances enable AI to generate personalized predictions regarding diagnosis, prognosis, therapeutic response, and disease progression while supporting increasingly sophisticated precision oncology applications.[13]

5. Genomics: The Foundation of Precision Medicine

Genomics remains the cornerstone of precision oncology because identification of actionable genetic alterations has revolutionized targeted cancer therapy. Next-generation sequencing technologies enable comprehensive characterization of somatic mutations, copy-number alterations, structural rearrangements, and inherited cancer susceptibility variants across numerous malignancies.[14]

Artificial intelligence enhances genomic medicine by prioritizing clinically relevant variants, predicting functional consequences of mutations, estimating drug sensitivity, identifying resistance mechanisms, and classifying tumors according to molecular subtypes. Machine learning algorithms also integrate genomic information with clinical outcomes to improve individualized risk prediction and therapeutic selection.

Despite these advances, genomic alterations alone frequently provide incomplete explanations for treatment response because downstream molecular processes ultimately determine tumor phenotype. Consequently, integration with additional omics layers has become increasingly important for comprehensive precision oncology.[15]

6. Transcriptomics and Gene Expression Analysis

Transcriptomics examines gene expression by quantifying messenger RNA molecules produced within tumor cells. Unlike genomic sequencing, which identifies static DNA alterations, transcriptomics reflects dynamic biological activity influenced by environmental conditions, therapeutic interventions, and cellular signaling pathways.[16]

Artificial intelligence analyzes complex gene-expression datasets to classify molecular cancer subtypes, identify prognostic biomarkers, estimate therapeutic sensitivity, and characterize tumor evolution. Deep learning models further integrate transcriptomic profiles with genomic, pathological, and clinical information to improve prediction of disease progression and treatment response.

Single-cell transcriptomics has expanded these capabilities by enabling characterization of individual cellular populations within tumors, revealing intratumoral heterogeneity, immune-cell interactions, and resistance mechanisms that remain hidden within conventional bulk sequencing approaches.[17]

7. Proteomics and Functional Biology

Proteins serve as the primary functional molecules responsible for virtually all cellular activities. Consequently, proteomics provides information that extends beyond genomic and transcriptomic analyses by directly measuring protein abundance, interactions, enzymatic activity, and post-translational modifications.[18]

Artificial intelligence enables comprehensive analysis of large-scale proteomic datasets generated through mass spectrometry and protein microarrays. Machine learning identifies protein signatures associated with cancer diagnosis, prognosis, therapeutic response, and drug resistance while revealing dysregulated signaling pathways involved in tumor progression.

Integration of proteomics with genomics and transcriptomics improves biomarker discovery because protein expression more directly reflects functional cellular behavior than genetic information alone. These combined approaches provide more accurate representations of disease biology and support increasingly personalized treatment strategies.[19]

8. Metabolomics, Lipidomics, and Systems Biology

Metabolomics investigates small-molecule metabolites that represent the final products of cellular biochemical processes, offering direct insight into tumor metabolism and physiological activity. Cancer cells frequently exhibit altered glucose metabolism, amino acid utilization, lipid synthesis, and mitochondrial function, making metabolomic profiling an important component of precision oncology.[20]

Artificial intelligence identifies metabolomic signatures associated with tumor subtype, therapeutic response, disease progression, and recurrence by integrating metabolic pathways with genomic, transcriptomic, and proteomic information. Lipidomics further complements these analyses by characterizing alterations in lipid metabolism, membrane signaling, and energy homeostasis that influence cancer development.

The integration of metabolomics, lipidomics, and other molecular layers supports systems biology approaches capable of describing cancer as a dynamic biological network rather than a collection of isolated molecular abnormalities. Such comprehensive analyses are expected to enhance biomarker discovery and improve individualized therapeutic decision-making across diverse malignancies.[21]

9. Multi-Omics Biomarker Discovery

One of the most significant advantages of multi-omics integration is the discovery of robust biomarkers that improve diagnosis, prognostic prediction, treatment selection, and disease monitoring. Artificial intelligence simultaneously analyzes genomic, transcriptomic, proteomic, metabolomic, epigenomic, and clinical datasets to identify biomarker combinations that outperform single-omics approaches.[22]

These integrated biomarker panels provide more comprehensive representations of tumor biology, facilitating earlier cancer detection, improved molecular classification, prediction of therapeutic response, and identification of patients at increased risk of recurrence. As computational methods continue to evolve, multi-omics biomarker discovery is expected to become a central component of next-generation precision oncology.

10. Multi-Omics for Personalized Cancer Therapy

The ultimate objective of precision oncology is to deliver the right treatment to the right patient at the right time. Multi-omics integration significantly enhances therapeutic decision-making by combining genomic alterations with transcriptomic activity, protein expression, metabolic pathways, immune characteristics, and clinical variables into comprehensive predictive models.[23]

Artificial intelligence analyzes these multidimensional datasets to estimate treatment response, identify mechanisms of drug resistance, predict adverse events, and recommend individualized therapeutic strategies. By integrating multiple biological layers, AI enables clinicians to select targeted therapies, immunotherapies, hormone therapies, chemotherapy regimens, and combination treatments that best match each patient's molecular profile.

Such comprehensive molecular characterization supports precision medicine that extends beyond single-gene mutations toward systems-level understanding of cancer biology.

11. Artificial Intelligence in Immunomics and Tumor Microenvironment Analysis

The tumor microenvironment plays a critical role in cancer progression, metastasis, and therapeutic response. In addition to malignant cells, tumors contain immune cells, stromal fibroblasts, endothelial cells, extracellular matrix components, cytokines, and microbial communities that collectively influence disease behavior.

Artificial intelligence integrates immunomic datasets with genomics, transcriptomics, proteomics, and digital pathology to characterize immune-cell composition, cytokine signaling, immune checkpoint expression, and spatial cellular interactions.[24]

Machine learning models predict responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and combination immunotherapies by analyzing the biological complexity of individual tumors. These approaches improve patient selection while supporting the development of increasingly personalized immunotherapeutic strategies.

12. Radiomics, Digital Pathology, and Multi-Modal Data Integration

Radiological imaging and digital pathology provide complementary phenotypic information that can be integrated with molecular datasets through artificial intelligence. Radiomics extracts quantitative imaging biomarkers describing tumor morphology, texture, vascularity, and spatial heterogeneity, whereas computational pathology evaluates microscopic tissue architecture, immune infiltration, stromal remodeling, and cellular organization.[25]

Multimodal AI combines these imaging-derived biomarkers with genomic, transcriptomic, proteomic, and metabolomic information to generate comprehensive patient representations. These integrated computational models improve cancer diagnosis, molecular subtype classification, prognostic prediction, treatment response assessment, and disease monitoring.

As multimodal learning continues to advance, radiology, pathology, and molecular biology are expected to become increasingly interconnected components of precision oncology.

13. Artificial Intelligence in Drug Discovery and Biomarker Development

The integration of multi-omics data with artificial intelligence is accelerating biomarker discovery and anticancer drug development. Machine learning algorithms analyze biological networks, signaling pathways, protein interactions, and molecular profiles to identify novel therapeutic targets and biomarkers associated with treatment response.[26]

Generative artificial intelligence further supports pharmaceutical research by designing candidate drug molecules, predicting molecular interactions, estimating toxicity profiles, and simulating biological responses before laboratory validation.

AI also enables identification of biomarker signatures for patient stratification in clinical trials, facilitating more efficient evaluation of targeted therapies and precision medicine strategies while reducing drug development costs and timelines.

14. Clinical Translation and Decision Support

Successful implementation of multi-omics precision oncology depends upon translating complex molecular information into clinically meaningful recommendations. Artificial intelligence-powered clinical decision-support systems integrate multi-omics datasets with laboratory investigations, medical imaging, pathology reports, electronic health records, and treatment histories to assist multidisciplinary oncology teams.[27]

Natural language processing automatically extracts clinically relevant information from scientific literature, pathology reports, physician notes, and clinical guidelines. AI subsequently synthesizes these heterogeneous data sources into individualized diagnostic assessments, prognostic predictions, treatment recommendations, and toxicity estimates.

Interactive visualization platforms enable clinicians to interpret complex molecular findings through intuitive dashboards, facilitating evidence-based decision-making while supporting personalized cancer management.

15. Challenges, Ethics, and Explainable Artificial Intelligence

Despite remarkable technological progress, integration of multi-omics and artificial intelligence into routine oncology practice remains associated with substantial challenges. Multi-omics datasets are characterized by extremely high dimensionality, heterogeneous formats, missing values, batch effects, and variable data quality, making computational integration inherently complex.[28]

Explainable artificial intelligence (XAI) has become increasingly important because clinicians require transparent explanations for AI-generated predictions before incorporating them into high-stakes clinical decisions. Techniques including SHAP (Shapley Additive Explanations), attention visualization, saliency mapping, and feature attribution improve interpretability while strengthening clinician confidence.

Additional challenges include algorithmic bias, interoperability limitations, patient privacy, cybersecurity, ethical governance, regulatory approval, computational infrastructure requirements, and unequal access to advanced molecular diagnostics. Addressing these issues will require standardized protocols, international collaboration, rigorous validation, and transparent regulatory frameworks.

16. Future Perspectives

The future of precision oncology lies in comprehensive systems biology approaches that integrate all available molecular, clinical, and imaging information into continuously learning computational ecosystems. Artificial intelligence will increasingly combine genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics, immunomics, radiomics, and digital pathology within unified predictive models.[29]

Foundation models trained on massive biomedical datasets are expected to provide generalized reasoning across multiple omics domains while requiring less task-specific retraining. Advances in single-cell sequencing, spatial transcriptomics, liquid biopsy, wearable health technologies, quantum computing, federated learning, and cloud-based healthcare infrastructure will further enhance the scalability and clinical applicability of AI-assisted precision oncology.

These innovations are expected to transform cancer care from reactive treatment toward predictive, preventive, adaptive, and highly personalized medicine.

17. Discussion

The integration of multi-omics technologies with artificial intelligence represents one of the most significant advances in precision oncology. By combining genomic, transcriptomic, proteomic, metabolomic, immunomic, radiological, pathological, and clinical information, AI provides comprehensive systems-level understanding of cancer biology that cannot be achieved through individual molecular datasets alone.

Applications spanning biomarker discovery, cancer diagnosis, prognostic prediction, treatment optimization, immunotherapy selection, drug discovery, and clinical decision support demonstrate the extraordinary potential of multi-omics AI for improving

patient outcomes. Nevertheless, widespread implementation requires overcoming important scientific, technical, ethical, and regulatory challenges through multidisciplinary collaboration, standardized methodologies, explainable algorithms, and prospective clinical validation.[30]

18. Conclusion

Precision oncology is evolving beyond genomics toward comprehensive multi-omics integration supported by advanced artificial intelligence. The combination of genomics, transcriptomics, proteomics, metabolomics, immunomics, radiomics, digital pathology, and clinical information provides a far more complete understanding of tumor biology than any individual data modality alone.

Artificial intelligence enables interpretation of these highly complex datasets through machine learning, deep learning, multimodal learning, graph neural networks, and foundation models, supporting more accurate diagnosis, improved prognostic prediction, individualized therapeutic selection, and enhanced biomarker discovery.

Although significant challenges related to data integration, explainability, ethics, interoperability, and regulatory implementation remain, continued advances in computational biology and systems medicine are steadily moving precision oncology toward truly personalized cancer care. The convergence of multi-omics and artificial intelligence is expected to become a defining foundation of next-generation oncology, ultimately improving clinical outcomes and advancing precision medicine worldwide.

References

1. Peter fernand, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', *Nature Reviews Clinical Oncology*, 20(4), pp. 267-283.
2. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', *Nature Genetics*, 45(10), pp. 1113-1120.
3. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', *IEEE Transactions on Medical Imaging*, 40(8), pp. 2021-2037.
4. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', *Nature*, 616(7956), pp. 259-265.
5. Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', *British Journal of Radiology*, 96(1150), Article 20230211.
6. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', *Nature Reviews Cancer*, 22(2), pp. 114-126.
7. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/321>, DOI: <https://doi.org/10.46121/pspc.51.4.4>
8. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/304>, DOI: <https://doi.org/10.46121/pspc.51.2.7>
9. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', *Cancer Cell*, 40(8), pp. 805-823.
10. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/323>, DOI: <https://doi.org/10.46121/pspc.51.4.5>
11. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/303>, DOI: <https://doi.org/10.46121/pspc.52.1.5>
12. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/426>, DOI: <https://doi.org/10.46121/pspc.53.4.38>
13. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/324>, DOI: <https://doi.org/10.46121/pspc.52.2.14>

14. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/311>, DOI: <https://doi.org/10.46121/pspc.52.2.12>
15. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/345>, DOI: <https://doi.org/10.46121/pspc.52.2.18>
16. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/388>, DOI: <https://doi.org/10.46121/pspc.51.4.7>
17. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OF TREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/305>, DOI: <https://doi.org/10.46121/pspc.53.2.31>
18. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/325>, DOI: <https://doi.org/10.46121/pspc.52.4.14>
19. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/326>, DOI: <https://doi.org/10.46121/pspc.53.3.21>
20. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/343>, DOI: <https://doi.org/10.46121/pspc.52.4.16>
21. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/327>, DOI: <https://doi.org/10.46121/pspc.53.4.33>
22. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
23. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: <https://pspac.info/index.php/dlbh/article/view/312>, DOI: <https://doi.org/10.46121/pspc.52.4.13>.
24. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
25. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/389>, DOI: <https://doi.org/10.46121/pspc.51.4.8>
26. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
27. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
28. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
29. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
30. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.